Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00906945 · ClinicalTrials.gov registry record · Phase 1
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00906945 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 39 participants.
The verdict
NCT00906945, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.
Interventions
- DRUG G-CSF
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Plerixafor
- DRUG Mitoxantrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00906945
The ClinicalTrials.gov registry entry for NCT00906945 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which G-CSF is the first listed.
NCT00906945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00906945 about?
NCT00906945 is a clinical study titled "Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia". This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.
What is the current status of trial NCT00906945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2011-02. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00906945?
The interventions under investigation include: G-CSF (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Plerixafor (DRUG), Mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT00906945?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.